All type of patients: 2 trials - EMILIA - TH3RESA
| trastuzumab emtansine vs lapatinib plus capecitabine | No demonstrated result suggested death (overall survival) by 32% (not demonstrated) suggested progression or death (progression free survival PFS) by 35% (not demonstrated) | |
| trastuzumab emtansine vs usual care | No demonstrated result suggested progression or death (progression free survival PFS) by 47% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
